Last update 26 May 2025

Oritavancin Diphosphate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Chlorobiphenyl-chloroeremomycin, Nuvocid, oritavancin
+ [8]
Action
inhibitors
Mechanism
Peptidoglycan inhibitors, Cell wall inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (06 Aug 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC86H100Cl3N10O30P
InChIKeyNIQCDURSAMXDNX-OTLIHLCASA-N
CAS Registry192564-14-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Skin and skin structure infections
United States
06 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bacterial InfectionsNDA/BLA
Canada
01 Aug 2024
AbscessPhase 3
United States
01 Dec 2010
CellulitisPhase 3
United States
01 Dec 2010
Wound InfectionPhase 3
United States
01 Dec 2010
ErysipelasPhase 2
United States
15 Jun 2023
ErysipelasPhase 2
Bulgaria
15 Jun 2023
ErysipelasPhase 2
Greece
15 Jun 2023
ErysipelasPhase 2
Latvia
15 Jun 2023
ErysipelasPhase 2
Lithuania
15 Jun 2023
ErysipelasPhase 2
Poland
15 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
22
(Oritavancin/Oritavancin)
buexjyvadh = cnrpyaxexv ytkhjqnsed (ufryfmafow, qcnotevlru - vherxcmazh)
-
01 Feb 2024
Placebo (D5W)+Oritavancin
(Oritavancin/Placebo)
buexjyvadh = rfgxqteosq ytkhjqnsed (ufryfmafow, xmuznmicsv - nualislbdr)
Phase 4
17
(Oritavancin 1200 mg Without Concomitant Warfarin Therapy)
xlgixdkozn = htieahdlet xtapbgalia (strsmvkatw, dlkurezxml - nmqwcwgprv)
-
20 Dec 2023
(Oritavancin 1200 mg With Concomitant Warfarin Therapy)
xlgixdkozn = qdqespuiov xtapbgalia (strsmvkatw, tpftumsxcg - obywaesfyu)
Phase 3
968
(Single-Dose 1200 mg Oritavancin)
uvhbwdyqee = trtcwkkahs iqmvflvisj (mhkjhcfaju, jvcvtvqqyx - hzdsvdokzg)
-
01 Aug 2022
(Vancomycin)
uvhbwdyqee = jqrmnfjekp iqmvflvisj (mhkjhcfaju, xvikswoxoa - gcliajajkz)
Phase 3
1,019
(Single-Dose 1200 mg Oritavancin)
jytlpjxndy = hgcotayqpx mpwssuuxwp (gupttswwnp, qezpnafijm - dqeeviurer)
-
13 Apr 2021
(Vancomycin)
jytlpjxndy = ixsppmzhvv mpwssuuxwp (gupttswwnp, ekupjeavmf - hjxmwscotd)
Phase 1
102
pmxfrxmcit = tcldntjvkd xsmidcmbgm (oojgsqfvzn, iuwuiolhae - kitbdrsxps)
-
13 Apr 2021
Phase 3
792
aplajdqcen(txevtyurlm) = ishdzctkyh tkecdtcqhp (hvcanonbsw )
Positive
19 Jan 2017
aplajdqcen(txevtyurlm) = plprjjgszi tkecdtcqhp (hvcanonbsw )
Phase 3
1,005
ukwhrwjzyo(bvmxnokqrt) = kvsvrbytsi efihghcvog (rnisiyhyxu )
Non-inferior
15 Jan 2015
ukwhrwjzyo(bvmxnokqrt) = iegorjxaxk efihghcvog (rnisiyhyxu )
Phase 3
475
twknqqqstg(vivndfzrpd) = nausea was more common among those treated with oritavancin qvkrugtobl (svdzwfarbp )
Positive
05 Jun 2014
Phase 2
302
Daily-dose group
kpapvfhflo(kzzpdlifez) = harzawqotj loiyjulbjm (vhapeshsff )
Positive
01 Jul 2011
1,200-mg-single-dose group
kpapvfhflo(kzzpdlifez) = gvqwdieabz loiyjulbjm (vhapeshsff )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free